These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 7628176)

  • 41. Opinion: anticipating change in drug development: the emerging era of translational medicine and therapeutics.
    Fitzgerald GA
    Nat Rev Drug Discov; 2005 Oct; 4(10):815-8. PubMed ID: 16224453
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A timely re-examination of drug polymorphism in pharmaceutical development and regulation.
    Grant DJ; Byrn SR
    Adv Drug Deliv Rev; 2004 Feb; 56(3):237-9. PubMed ID: 14962580
    [No Abstract]   [Full Text] [Related]  

  • 43. US new drug applications increasingly rely on trials conducted abroad.
    Tanne JH
    BMJ; 2010 Jul; 341():c3616. PubMed ID: 20605887
    [No Abstract]   [Full Text] [Related]  

  • 44. Former pharma pitchman: beware of new drugs. An industry insider advises considering the older options if you need a prescription. Interview by Sarah Baldauf.
    Nesi T
    US News World Rep; 2008 Nov 3-10; 145(10):64. PubMed ID: 18998444
    [No Abstract]   [Full Text] [Related]  

  • 45. Harm from prescription drugs likely to grow, claims US sociologist.
    Kermode-Scott B
    BMJ; 2008 Aug; 337():a1280. PubMed ID: 18701565
    [No Abstract]   [Full Text] [Related]  

  • 46. US policy keeps drugs out of reach in clinical trials abroad.
    Check E
    Nat Med; 2005 May; 11(5):460. PubMed ID: 15875037
    [No Abstract]   [Full Text] [Related]  

  • 47. Drugs that made headlines in 2015.
    Chakradhar S
    Nat Med; 2015 Dec; 21(12):1382-3. PubMed ID: 26646488
    [No Abstract]   [Full Text] [Related]  

  • 48. Drug pipeline: Q311.
    Peng W
    Nat Biotechnol; 2011 Oct; 29(10):859. PubMed ID: 21997619
    [No Abstract]   [Full Text] [Related]  

  • 49. Finance fibrillation and research rhythm: do we need a pacemaker?
    Apolone G; Patarnello F
    J Ambul Care Manage; 2008; 31(2):187-9. PubMed ID: 18360180
    [No Abstract]   [Full Text] [Related]  

  • 50. Clinical development of therapeutic recombinant proteins.
    Reichert JM; Paquette C
    Biotechniques; 2003 Jul; 35(1):176-8, 180, 182-5. PubMed ID: 12866419
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New drug approval times and 'therapeutic potential' in Canada, Australia, Sweden and the United States during the period 1992 to 1998.
    Rawson NS; Kaitin KI
    Can J Clin Pharmacol; 2000; 7(2):97-101. PubMed ID: 10958705
    [TBL] [Abstract][Full Text] [Related]  

  • 52. "Getting the dose right": facts, a blueprint, and encouragements.
    Peck CC; Cross JT
    Clin Pharmacol Ther; 2007 Jul; 82(1):12-4. PubMed ID: 17571068
    [No Abstract]   [Full Text] [Related]  

  • 53. Editorial: time to end the death trials.
    James JS
    AIDS Treat News; 1996 Aug; (no 252):1-4. PubMed ID: 11363751
    [TBL] [Abstract][Full Text] [Related]  

  • 54. When is a medical product too risky? An interview with FDA's top drug official. Interview by Tamar Nordenberg.
    Woodcock J
    FDA Consum; 1999; 33(5):8-11, 13. PubMed ID: 10522164
    [No Abstract]   [Full Text] [Related]  

  • 55. A comparison of new drug availability in Canada and the United States and potential therapeutic implications of differences.
    Lexchin J
    Health Policy; 2006 Dec; 79(2-3):214-20. PubMed ID: 16472888
    [TBL] [Abstract][Full Text] [Related]  

  • 56. FDA policy and regulation of stereoisomers: paradigm shift and the future of safer, more effective drugs.
    Strong M
    Food Drug Law J; 1999; 54(3):463-87. PubMed ID: 11797710
    [No Abstract]   [Full Text] [Related]  

  • 57. Regulating the fate of pharmaceutical drugs: a new prescription for the environment.
    Nidel CT
    Food Drug Law J; 2003; 58(1):81-101. PubMed ID: 12739585
    [No Abstract]   [Full Text] [Related]  

  • 58. The drug lag: new drug introductions in India in comparison to United States.
    Karan RS; Malhotra S; Pandhi P
    J Assoc Physicians India; 2002 Jun; 50():782-7. PubMed ID: 12240842
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analysis of the success rates of new drug development in Japan and the lag behind the US.
    Hirai Y; Yamanaka Y; Kusama M; Ishibashi T; Sugiyama Y; Ono S
    Health Policy; 2012 Mar; 104(3):241-6. PubMed ID: 22172246
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ethical implications of pediatric drug research policy initiatives.
    Twomey JG
    IRB; 2000; 22(2):5-10. PubMed ID: 11883466
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.